Equities
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in USDIncome statement in USDView more

Year on year Resmed Inc grew revenues 10.95% from 4.22bn to 4.69bn while net income improved 13.75% from 897.56m to 1.02bn.
Gross margin57.67%
Net profit margin23.15%
Operating margin29.50%
Return on assets15.94%
Return on equity23.56%
Return on investment18.11%
More ▼

Cash flow in USDView more

In 2024, Resmed Inc did not generate a significant amount of cash. However, the company earned 1.40bn from its operations for a Cash Flow Margin of 29.91%. In addition the company used 269.78m on investing activities and also paid 1.12bn in financing cash flows.
Cash flow per share8.74
Price/Cash flow per share28.73
Book value per share35.39
Tangible book value per share12.47
More ▼

Balance sheet in USDView more

Resmed Inc has a Debt to Total Capital ratio of 11.54%, a lower figure than the previous year's 31.80%.
Current ratio2.92
Quick ratio1.91
Total debt/total equity0.1304
Total debt/total capital0.1154
More ▼

Growth rates in USD

SmartText is unavailable
Div yield(5 year avg)0.80%
Div growth rate (5 year)5.34%
Payout ratio (TTM)26.02%
EPS growth(5 years)19.48
EPS (TTM) vs
TTM 1 year ago
22.72
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.